Terns Pharmaceuticals to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.–()–Terns Pharmaceuticals, Inc., a biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease, today announced that the Company’s management team will present at two upcoming investor conferences.

Piper Sandler EASL Takeaway Series Featuring Experts & Drug Developers

  • Date: Wednesday, September 2nd
  • Time: 11:30 a.m. ET
  • Speakers: Senthil Sundaram, CEO and Erin Quirk, M.D., President and CMO

Citi’s 15th Annual BioPharma Virtual Conference

  • Date: Tuesday, September 8th
  • Time: 3:30 p.m. ET
  • Speaker: Senthil Sundaram, CEO

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class single-agent and combination therapies to treat liver disease including a pipeline of orally administered drug candidates for the treatment of non-alcoholic steatohepatitis (NASH). The company’s liver-selective FXR-agonist, TERN-101, is currently enrolling a multi-center, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate efficacy, safety, and pharmacokinetics in 96 presumed NASH patients who receive placebo or TERN-101 at various dose levels for 12 weeks. Terns announced in July 2020 positive Phase 1 clinical data for its highly-selective SSAO inhibitor, TERN-201, demonstrating potent and sustained target engagement. In addition, the company is actively planning to initiate clinical studies for its thyroid hormone receptor-β agonist TERN-501 as monotherapy and in combination with its other pipeline assets for NASH, as well as advancing its small molecule GLP-1R agonist program. Terns’ investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.

For more information, visit www.ternspharma.com

Source

About the Author: Biotech Today

You might like